Valproate must no longer be used in any woman or girl able to have children unless she has a pregnancy prevention programme in place. This is designed to make sure patients are fully aware of the risks and the need to avoid becoming pregnant. ¹
The CMDh has endorsed the strengthened regulatory position on valproate medicines which MHRA has been championing through the Europe-wide review.
These new regulatory measures also include a ban on the use of valproate for a migraine or bipolar disorder during pregnancy and a ban on the use of valproate to treat epilepsy during pregnancy unless there is no other effective treatment available.